GlassScriptPhysician profile
Jordan Davis
NPI 1780277608
$4,959.91
in general payments reported to CMS, 2019-2025
26 companies · $3,048 in 2025
The $3,048 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $641 · 2022: $488 · 2023: $287 · 2024: $495 · 2025: $3,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,500 · Travel and Lodging: $1,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,500.38 |
| Travel and Lodging | $1,330.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $2,619.78 | 2023-2025 | Evoke, Evoke Scs |
| Boston Scientific Corporation | $610.69 | 2021-2022 | |
| Axsome Therapeutics, INC. | $314.83 | 2024-2025 | Auvelity |
| Medtronic, INC. | $189.69 | 2021-2025 | Intellis Adaptivestim, Synchromedii, Accurian |
| Nevro Corp. | $163.55 | 2021-2023 | Senza |
| Pacira Pharmaceuticals Incorporated | $142.71 | 2021-2025 | Zilretta, Exparel, Iovera |
| E.R. Squibb & Sons, L.L.C. | $105.65 | 2025 | Cobenfy |
| Alkermes, INC. | $86.60 | 2025 | Lybalvi |
| Abbvie INC. | $85.38 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.75 | 2024-2025 | Relistor |
| Valinor Pharma, LLC | $62.91 | 2023-2024 | Movantik |
| Tris Pharma INC | $57.17 | 2024-2025 | Dyanavel Xr |
| Almatica Pharma LLC | $57.00 | 2021-2024 | Loreev Xr |
| Azurity Pharmaceuticals, INC. | $53.50 | 2023-2024 | Horizant, Horizant |
| Arbor Pharmaceuticals, INC. | $48.47 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $40.61 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.93 | 2024-2025 | Trintellix |
| Globus Medical, INC. | $34.98 | 2025 | Senza |
| Averitas Pharma INC. | $24.21 | 2023 | Qutenza |
| Grt US Holding, INC. | $23.96 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.95 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $22.72 | 2024 | Rexulti |
| Redhill Biopharma INC. | $21.64 | 2021 | |
| Janssen Pharmaceuticals, INC | $19.42 | 2025 | Spravato |
| Spinal Simplicity, LLC | $18.01 | 2024 | Ha Minuteman G3-R |
| Noven Therapeutics, LLC | $13.80 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.